Edward Myles
Director Financiero/CFO en SCHOLAR ROCK HOLDING CORPORATION .
Fortuna: 348 595 $ al 30/04/2024
Cargos activos de Edward Myles
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| SCHOLAR ROCK HOLDING CORPORATION | Director Financiero/CFO | 16/07/2020 | - |
| Director de Operaciones | 16/07/2020 | - | |
| Director/Miembro de la Junta | 19/11/2018 | 16/07/2020 | |
| Independent Dir/Board Member | 19/11/2018 | 16/07/2020 | |
Scholar Rock, Inc.
 Scholar Rock, Inc. BiotechnologyHealth Technology Scholar Rock, Inc. operates as a biotechnology company. It focuses on discovering and developing a novel class of biologic therapies that target supracellular activation of growth factors in the disease microenvironment. The company was founded by Timothy Springer and Leonard Zon and is headquartered in Cambridge, MA. | Director Financiero/CFO | 16/07/2020 | - |
| Director de Operaciones | 16/07/2020 | - | |
| Director/Miembro de la Junta | 01/11/2018 | 16/07/2020 |
Historial de carrera de Edward Myles
Antiguos cargos conocidos de Edward Myles.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| AMAG PHARMACEUTICALS, INC. | Comptroller/Controller/Auditor | 11/04/2016 | - |
| Director de Operaciones | 09/01/2020 | 11/06/2020 | |
| Director Financiero/CFO | 11/04/2016 | 11/06/2020 | |
| Treasurer | 11/04/2016 | 11/06/2020 | |
| OCATA THERAPEUTICS INC | Director de Operaciones | 22/05/2014 | 10/02/2016 |
| Director Financiero/CFO | 23/05/2013 | 10/02/2016 | |
| Presidente | 21/01/2014 | 25/06/2014 | |
PrimeraDx, Inc.
 PrimeraDx, Inc. Medical SpecialtiesHealth Technology PrimeraDx, Inc. develops and commercializes molecular diagnostics systems. It offers ICEPlex System, an open platform that allows clinical researchers to design their assays for the development of multiplexed, multimodal, and quantitative in vitro diagnostic to simultaneously interrogate dozens of biomarkers in the same reaction. The company's ICEPlex System also enables to design complex multi-modal assays that test for disparate target types, such as SNPs, expression biomarkers, miRNAs, and fusion genes, as well as addresses research challenges in oncology, infectious diseases, translational medicine research, and pharma quality control. It also focuses on developing oncology products that are intended to support cancer research, diagnostics, and therapeutics; and companion diagnostics solutions that help pharmaceutical companies to design, develop, and validate custom CDx tests. The company was founded by Vladimir I. Slepnev in 2004 and is headquartered in Mansfield, MA. | Director de Operaciones | 24/03/2011 | 01/06/2013 |
| Director Financiero/CFO | 25/09/2009 | 01/06/2013 | |
| PRESSURE BIOSCIENCES, INC. | Director Financiero/CFO | 03/04/2006 | 04/11/2008 |
EMD Pharmaceuticals, Inc.
 EMD Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Part of Merck KGaA, EMD Pharmaceuticals, Inc. is a company that manufactures pharmaceutical preparations. The company is based in Durham, NC. The company was founded by Nancy J. Wysenski. | Comptroller/Controller/Auditor | 01/05/2003 | 01/04/2006 |
| SG Cowen Securities Corp. | Corporate Officer/Principal | 01/01/2001 | 01/01/2003 |
Boston Biomedical, Inc.
 Boston Biomedical, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sumitomo Chemical Co., Ltd., Boston Biomedical, Inc. is a developer of novel cancer therapeutics with the goal of significantly improving patient outcomes. The company is based in Norwood, MA. The company's most advanced research programs are focused on investigational agents that inhibit multiple oncogenic pathways, including cancer stemness pathways, and modifying immune responses. The company was founded by Chiang J. Li. Boston Biomedical was acquired by Sumitomo Pharma Co., Ltd. on April 25, 2012 for $2,630 million. | Comptroller/Controller/Auditor | 01/01/1997 | 01/01/2000 |
| ░░░░░░░░░░░░░░░░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░ ░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
| ░░░░ ░░░░░░ ░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
| ░░░░░░░░ ░░ ░░░░░░░░░░░ | - | - | |
| ░░░░░░░░░ | - | - | |
| ░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
Formación de Edward Myles.
| University of Hartford | Undergraduate Degree |
| Olin Business School | Masters Business Admin |
Estadísticas
Internacional
| Estados Unidos | 14 |
| Alemania | 2 |
| Polonia | 2 |
Operativa
| Director of Finance/CFO | 7 |
| Chief Operating Officer | 5 |
| Corporate Officer/Principal | 4 |
Sectorial
| Health Technology | 10 |
| Commercial Services | 4 |
| Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| PRESSURE BIOSCIENCES, INC. | Health Technology |
| MERCK KGAA | Health Technology |
| SCHOLAR ROCK HOLDING CORPORATION | Health Technology |
| Empresas privadas | 10 |
|---|---|
AMAG Pharma USA, Inc.
 AMAG Pharma USA, Inc. Pharmaceuticals: MajorHealth Technology AMAG Pharma USA, Inc. engages in the provision of pharmaceutical products to independent pharmacies, managed care organizations, hospitals, pharmacy benefit management companies, government entities, and physicians. The company was founded by Victor M. Hermelin in 1942 and is headquartered in Waltham, MA. | Health Technology |
PricewaterhouseCoopers LLP
 PricewaterhouseCoopers LLP Miscellaneous Commercial ServicesCommercial Services PricewaterhouseCoopers LLC provides assurance, tax and advisory services. Its services include audit and assurance, consulting, deals, human resources, legal, tax, and family business. The firm also offers accountability, risk management, structuring, mergers and acquisitions, and performance and process improvement. The company was founded in 1998 and is headquartered in Buffalo, NY. | Commercial Services |
PrimeraDx, Inc.
PrimeraDx, Inc. Medical SpecialtiesHealth Technology PrimeraDx, Inc. develops and commercializes molecular diagnostics systems. It offers ICEPlex System, an open platform that allows clinical researchers to design their assays for the development of multiplexed, multimodal, and quantitative in vitro diagnostic to simultaneously interrogate dozens of biomarkers in the same reaction. The company's ICEPlex System also enables to design complex multi-modal assays that test for disparate target types, such as SNPs, expression biomarkers, miRNAs, and fusion genes, as well as addresses research challenges in oncology, infectious diseases, translational medicine research, and pharma quality control. It also focuses on developing oncology products that are intended to support cancer research, diagnostics, and therapeutics; and companion diagnostics solutions that help pharmaceutical companies to design, develop, and validate custom CDx tests. The company was founded by Vladimir I. Slepnev in 2004 and is headquartered in Mansfield, MA. | Health Technology |
EMD Pharmaceuticals, Inc.
EMD Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Part of Merck KGaA, EMD Pharmaceuticals, Inc. is a company that manufactures pharmaceutical preparations. The company is based in Durham, NC. The company was founded by Nancy J. Wysenski. | Health Technology |
| SG Cowen Securities Corp. | Finance |
Astellas Institute for Regenerative Medicine
 Astellas Institute for Regenerative Medicine Pharmaceuticals: MajorHealth Technology Astellas Institute for Regenerative Medicine engages in the development and commercialization of human pluripotent stem cell technology in the field of regenerative medicine. The company also have a preclinical development pipeline in areas outside of ophthalmology, including; autoimmune diseases, inflammatory diseases, and wound healing. The company was founded on May 18, 2000 and is headquartered in Marlborough, MA. | Health Technology |
AMAG Pharmaceuticals, Inc.
 AMAG Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. Its products include Makena and Feraheme. It focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It also manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. The company was founded on November 9, 1981 and is headquartered in Waltham, MA. | Health Technology |
Boston Biomedical, Inc.
Boston Biomedical, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sumitomo Chemical Co., Ltd., Boston Biomedical, Inc. is a developer of novel cancer therapeutics with the goal of significantly improving patient outcomes. The company is based in Norwood, MA. The company's most advanced research programs are focused on investigational agents that inhibit multiple oncogenic pathways, including cancer stemness pathways, and modifying immune responses. The company was founded by Chiang J. Li. Boston Biomedical was acquired by Sumitomo Pharma Co., Ltd. on April 25, 2012 for $2,630 million. | Commercial Services |
Scholar Rock, Inc.
Scholar Rock, Inc. BiotechnologyHealth Technology Scholar Rock, Inc. operates as a biotechnology company. It focuses on discovering and developing a novel class of biologic therapies that target supracellular activation of growth factors in the disease microenvironment. The company was founded by Timothy Springer and Leonard Zon and is headquartered in Cambridge, MA. | Health Technology |
| Coopers & Lybrand LLP | Commercial Services |
- Bolsa de valores
- Insiders
- Edward Myles
- Experiencia